ライフサイエンスコーパス: deep vein thrombosis

1 patient had central venous catheter-related deep vein thrombosis.

2 embolism manifested as pulmonary embolism or deep vein thrombosis.

3 none or placebo stockings) in patients with deep vein thrombosis.

4 even patients (84.6%) had cannula-associated deep vein thrombosis.

5 al stay less than 2 days, or had preexisting deep vein thrombosis.

6 ng post thrombotic syndrome in patients with deep vein thrombosis.

7 es analysed were mortality and recurrence of deep vein thrombosis.

8 , or between extrapulmonary tuberculosis and deep vein thrombosis.

9 t thrombus organization in a murine model of deep vein thrombosis.

10 ation and PAD4 as potential drug targets for deep vein thrombosis.

11 as the source of the prothrombotic effect in deep vein thrombosis.

12 ment of such diseases as atherosclerosis and deep vein thrombosis.

13 and all of them developed cannula-associated deep vein thrombosis.

14 l thromboplastin time, prothrombin time, and deep vein thrombosis.

15 both femoral and jugular cannula-associated deep vein thrombosis.

16 tor for VTEs, such as pulmonary embolism and deep vein thrombosis.

17 sociated risk factors for cannula-associated deep vein thrombosis.

18 le scans, 92 (34%, 95% CI 28-40) had femoral deep vein thrombosis.

19 ndrome (PTS) in patients with acute proximal deep vein thrombosis.

20 omboembolic events, driven by a reduction in deep vein thrombosis.

21 17), and survival (p=0.45) were unrelated to deep vein thrombosis.

22 anced cancer admitted to SPCUs had a femoral deep vein thrombosis.

23 imb oedema (p=0.009) independently predicted deep vein thrombosis.

24 of PCDT in ATTRACT patients with iliofemoral deep vein thrombosis.

25 14.5% mortality, 43.7% disability, and 9.8% deep vein thrombosis.

26 and unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

27 elated bloodstream infection and symptomatic deep-vein thrombosis.

28 erythrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

29 The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmon

30 were possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterio

31 ermittent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylax

32 evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.

33 receiving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TA

34 r and thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2

35 ially lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and s

36 common grade three or higher toxicities were deep-vein thrombosis, 57 (26%) of 223 versus 27 (12%) of

37 ffective than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk r

38 for pulmonary embolism, 1% (29 of 2327) for deep vein thrombosis, 7% (61 of 866) for sepsis, 16% (22

39 cal practice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4

40 ved for interventions for pulmonary embolism/deep vein thrombosis (A 0%, B 24%, C 76%), inferior vena

41 Finally, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrom

42 y status of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% c

43 Cannula-associated deep vein thrombosis after venovenous extracorporeal mem

44 ; secondary endpoints were the occurrence of deep vein thrombosis alone, pulmonary embolism alone.

45 thrombus and plasma of baboons subjected to deep vein thrombosis, an example of inflammation-enhance

46 The FN rate was 1.14% (8/701; 7 deep vein thrombosis and 1 PE) for pooled normal, very l

47 tional interpretations versus 1.5% (9/585, 5 deep vein thrombosis and 4 PE) in trinary interpretation

48 address this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in pept

49 romboembolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as

50 ontribute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

51 Effects of stasis-induced deep vein thrombosis and fibrinolysis on thrombosis were

52 mbolisms occurred, including six symptomatic deep vein thrombosis and four pulmonary emboli, resultin

53 ion, and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thr

54 tamoxifen and 16 with placebo, including one deep vein thrombosis and one stage I endometrial cancer

55 arin infusion is recommended for symptomatic deep vein thrombosis and portal and mesenteric vein thro

56 tect source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

57 Deep Vein Thrombosis and pulmonary embolism (DVT/PE) is

58 In many patients with deep vein thrombosis and pulmonary embolism (venous thro

59 Deep vein thrombosis and pulmonary embolism are major he

60 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

61 or the initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as f

62 Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism in 2008 has

63 type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-s

64 mber 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assesse

65 ct on venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the ev

66 Deep vein thrombosis and pulmonary embolism, collectivel

67 omes and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed b

68 Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is a common

69 y makes it the drug of choice for preventing deep vein thrombosis and pulmonary embolism.

70 ant agents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

71 ovoked and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

72 Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

73 the mortality and morbidity associated with deep vein thrombosis and pulmonary embolism.

74 e patient (7.7%) had both cannula-associated deep vein thrombosis and pulmonary embolism.

75 ent and included serious adverse events (eg, deep vein thrombosis and systemic complications) and min

76 diagnosis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2

77 n between FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable

78 ostic techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary a

79 pulmonary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism

80 he first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data

81 e comprise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise ven

82 or the treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been sho

83 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecif

84 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

85 ome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembol

86 re hospitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent

87 e events were one event each of hypotension, deep vein thrombosis, and hypophosphatemia.

88 failure, urinary tract infection, pneumonia, deep vein thrombosis, and myocardial infarction were ind

89 ons such as ventilator-associated pneumonia, deep vein thrombosis, and pressure sores; and shortened

90 ors for venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing

91 ons including myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism.

92 ere obtained for provoked/unprovoked events, deep vein thrombosis, and pulmonary embolism.

93 hree patients had femoral cannula-associated deep vein thrombosis, and two had an oxygenator or pump

94 s, any infection, hemorrhage, renal failure, deep vein thrombosis, and uncontrollable intracranial hy

95 no IVC filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patient

96 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism

97 ) with an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive antic

98 Preoperative albumin, postoperative deep-vein thrombosis, and electrolyte levels were associ

99 ostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

100 edications included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a st

101 outcome was the composite of any symptomatic deep-vein thrombosis, any nonfatal pulmonary embolism, a

102 Outcomes for graft and deep vein thrombosis are not favorable.

103 was incident (i.e., new) proximal lower-limb deep-vein thrombosis, as detected on twice-weekly lower-

104 ein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of system

105 lism), we randomly assigned patients without deep-vein thrombosis at screening to receive rivaroxaban

106 he treatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment.

107 and symptoms plus imaging-confirmed proximal deep vein thrombosis but no chest imaging.

108 o difference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary emb

109 arket and are believed to reduce the risk of deep vein thrombosis by 40%.

110 Stasis of venous blood triggers deep vein thrombosis by activating coagulation, yet its

111 eduction in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.7

112 mortality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

113 requently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulan

114 e, non-interventional study of patients with deep-vein thrombosis, done in hospitals and community ca

115 8-year-old German-Caucasian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of righ

116 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary emb

117 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonar

118 Deep vein thrombosis (DVT) and its complication, pulmona

119 carefully selected patients with cancer with deep vein thrombosis (DVT) and low-risk pulmonary emboli

120 Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE),

121 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

122 Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE),

123 ratively may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

124 Deep vein thrombosis (DVT) and pulmonary embolism are co

125 Deep vein thrombosis (DVT) and pulmonary embolism are co

126 Monitoring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule

127 Accurate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical pro

128 Deep vein thrombosis (DVT) is a common but unpredictable

129 Deep vein thrombosis (DVT) is a common cardiovascular di

130 Deep vein thrombosis (DVT) is a major cause of cardiovas

131 ssessment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge

132 The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persi

133 Deep vein thrombosis (DVT) isolated to the calf veins (d

134 icoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

135 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a

136 Both IPC and GCS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patie

137 luation on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthop

138 (4) deep vein thrombosis (DVT) prophylaxis was independent o

139 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates re

140 Incidence rates for lower extremity deep vein thrombosis (DVT) range from 88 to 112 per 100

141 Deep vein thrombosis (DVT) with its major complication,

142 ght lower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect rela

143 Deep vein thrombosis (DVT), caused by alterations in ven

144 In patients with suspected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS)

145 actor, or a first unprovoked isolated distal deep vein thrombosis (DVT), generally should be treated

146 or a first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence

147 In patients with acute deep vein thrombosis (DVT), pharmacomechanical catheter-

148 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and

149 normal clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive p

150 ority of them have proximal limb-threatening deep vein thrombosis (DVT).

151 rtality, all-cause mortality, and subsequent deep vein thrombosis (DVT).

152 resolution in humans after acute symptomatic deep vein thrombosis (DVT).

153 t-thrombotic syndrome (PTS) in patients with deep vein thrombosis (DVT).

154 uperficial thrombosis and the development of deep vein thrombosis (DVT).

155 in both formation and resolution of clots in deep vein thrombosis (DVT).

156 Deep-vein thrombosis (DVT) is regarded a chronic disease

157 FVL mutation poses a clearly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

158 hlegmasia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was no

159 ab group, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemoth

160 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolis

161 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis enrolled 1650 patients aged 65 year

162 there were qualitative differences such that deep vein thrombosis exclusively afflicted the immunosup

163 The prevalence of deep vein thrombosis following decannulation from extrac

164 y were to: 1) analyze the cannula-associated deep vein thrombosis frequency after venovenous extracor

165 Risk factors for deep-vein thrombosis have been shown not to be always th

166 ceding week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0

167 r the risk for developing cannula-associated deep vein thrombosis (hazard ratio, 0.98; 95% CI, 0.98-1

168 also a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1

169 from the YEARS algorithm (clinical signs of deep-vein thrombosis, hemoptysis, and pulmonary embolism

170 rtions of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thy

171 P = 0.003]; mainly driven by a reduction in deep vein thrombosis (HR 0.523; 95% CI 0.349-0.783, P =

172 al [CI], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.0

173 frapopliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed i

174 n ultrasonography for women with symptoms of deep-vein thrombosis; if the results were positive (i.e.

175 Principal outcomes were deep vein thrombosis in both the lower and upper extremi

176 termine prevalence and predictors of femoral deep vein thrombosis in patients admitted to specialist

177 The prevalence of deep vein thrombosis in the cannulated vessel following

178 describe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults

179 rategies are more effective in prevention of deep vein thrombosis in the elective total knee replacem

180 p-vein thrombosis in an upper limb or distal deep-vein thrombosis in a lower limb, and death from ven

181 composite of objectively confirmed proximal deep-vein thrombosis in a lower limb, pulmonary embolism

182 lower limb, pulmonary embolism, symptomatic deep-vein thrombosis in an upper limb or distal deep-vei

183 was symptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embo

184 right-sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95

185 were significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared wit

186 The use of thrombolysis for occlusive deep vein thrombosis, in attempt to reduce the long-term

187 y disseminated intravascular coagulation and deep vein thrombosis, in tuberculosis (TB) patients.

188 , 2.22; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% co

189 ormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or

190 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients

191 ltrate the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue

192 er randomized trial, 391 patients with acute deep vein thrombosis involving the iliac or common femor

193 Deep vein thrombosis is a major global health issue, res

194 e of symptomatic central venous line-related deep vein thrombosis is associated with worse outcomes,

195 treatment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States

196 ow-up, acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systo

197 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the add

198 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic

199 s a leading cause of maternal mortality, and deep vein thrombosis leads to maternal morbidity, with p

200 pulmonary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 m

201 redictors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paral

202 onary artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-react

203 nnulation induced femoral cannula-associated deep vein thrombosis more frequently than femorojugular

204 , but also contribute to the pathogenesis of deep vein thrombosis, myocardial infarction and stroke.

205 mortality in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

206 (n = 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and

207 y adverse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2

208 nterventions; n=15 028) were included in the deep vein thrombosis network, 12 in the pulmonary emboli

209 efficacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or al

210 ts (catheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, ble

211 Deep vein thrombosis occurred in 5 patients.

212 bolism (pulmonary embolism or any lower-limb deep-vein thrombosis) occurred in 103 of 991 patients (1

213 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

214 s Seminar, we discuss pulmonary embolism and deep vein thrombosis of the legs.

215 Four participants with a scan showing no deep vein thrombosis on admission developed a deep vein

216 eep vein thrombosis on admission developed a deep vein thrombosis on repeat scanning over 21 days.

217 0.41 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respective

218 eported for 2 of 162 children (1.2%) who had deep vein thrombosis or central-line thrombosis as their

219 may arise from intravenous obstruction after deep vein thrombosis or from extrinsic venous compressio

220 us thromboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary emb

221 A FN study was defined as development of deep vein thrombosis or PE within 3 months after a negat

222 y, independent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time o

223 with inflammatory bowel disease who develop deep vein thrombosis or pulmonary embolism often have ac

224 dy outcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurre

225 zation, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) were assesse

226 with newly diagnosed venous thromboembolism (deep vein thrombosis or pulmonary embolism) who were new

227 or cerebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respira

228 days after surgery or confirmed symptomatic deep vein thrombosis or pulmonary embolism).

229 onfirmed with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary

230 ged at least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embo

231 oagulant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9

232 had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive or

233 ated use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed

234 cial-vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression

235 icacy outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression

236 3] vs 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [

237 Cs were associated with an increased risk of deep vein thrombosis (OR 2.55, 1.54-4.23, p<0.0001) but

238 n of statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults we

239 nd collected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

240 botic events (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorr

241 mboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-

242 ath (P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

243 In patients with acute iliofemoral deep vein thrombosis, PCDT did not influence the occurre

244 laxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0

245 95% confidence interval [CI], 0.77 to 0.91), deep vein thrombosis prophylaxis (OR, 0.88; 95% CI, 0.83

246 flow, improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall pe

247 management, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic inte

248 oley catheter removal, R = -0.089 [P = .63]; deep vein thrombosis prophylaxis, R = 0.101 [P = .59]).

249 Measure documentation, lipid management, and deep vein thrombosis prophylaxis.

250 edical complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia)

251 ing (micro)thrombotic complications, such as deep vein thrombosis, pulmonary embolism, and stroke.

252 omatic venous thromboembolism was defined as deep vein thrombosis, pulmonary embolism, or both, diagn

253 s of acute renal failure requiring dialysis, deep vein thrombosis, pulmonary embolism, sepsis, pneumo

254 ents ranging from repeated thrombophlebitis, deep vein thrombosis, pulmonary embolism, transitory isc

255 composite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thro

256 rade 3 to 5 nonhematologic toxicity included deep vein thrombosis/pulmonary embolism (21%), hemorrhag

257 ively), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%)

258 With the baseline PICC-related deep vein thrombosis rate of 2.7% and pooled OR of 2.55,

259 oled RR, 4.30 95% CI, 1.60-11.54) and higher deep vein thrombosis rates (2.94 1.35-6.38).

260 ransgenic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate

261 analysis of 11 studies comparing the risk of deep vein thrombosis related to PICCs with that related

262 ophylaxis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-

263 o significant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-

264 Deep vein thrombosis remains a major health problem nece

265 of post thrombotic syndrome in patients with deep vein thrombosis remains unknown.

266 fibrillation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasi

267 28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.

268 CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.

269 , 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.

270 Rivaroxaban ranked first for prevention of deep vein thrombosis (RR 0.12 [95% CrI 0.06-0.22]).

271 clinical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion aft

272 Deep vein thrombosis screening was performed using a rig

273 re observed in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary s

274 Outcomes of interest were deep vein thrombosis (symptomatic and asymptomatic), pul

275 PICCs are associated with a higher risk of deep vein thrombosis than are CVCs, especially in patien

276 hylaxis would result in a lower incidence of deep-vein thrombosis than pharmacologic thromboprophylax

277 antly lower incidence of proximal lower-limb deep-vein thrombosis than pharmacologic thromboprophylax

278 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical

279 o cases), pulmonary embolus (two cases), and deep-vein thrombosis (three cases).

280 ly assigned 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation a

281 cal trial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter

282 ents (76.9%) had isolated cannula-associated deep vein thrombosis, two patients (15.4%) had isolated

283 haracterization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic s

284 in the thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokine

285 Femoral deep vein thrombosis was diagnosed in 5 of 12 patients w

286 Cannula-associated deep vein thrombosis was found in 75 patients (71.4%) de

287 dies, the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were cr

288 8%), a femoral associated cannula-associated deep vein thrombosis was identified in 10 patients (76.9

289 A jugular associated cannula-associated deep vein thrombosis was identified in seven patients (5

290 Deep vein thrombosis was induced in the inferior vena ca

291 Deep vein thrombosis was not associated with thromboprop

292 Deep vein thrombosis was present only in five of 41 (12.

293 During follow-up, popliteal deep-vein thrombosis was diagnosed in 1 patient (0.21%;

294 h comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure

295 mptomatic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twi

296 screened high-risk patients, 20 asymptomatic deep vein thrombosis were detected with venous duplex ul

297 21 years, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasou

298 ptomatic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban

299 t of the study was the prevalence of femoral deep vein thrombosis within 48 h of SPCU admission, anal

300 d anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory mo